On the 14 May 2021 between 1.00pm – 4.15pm, we will be running our half-day virtual meeting “Current Conversations in Cardiovascular Disease” , which will cover controversies and debate within CVD management across a variety of focused topics. Each session will welcome a multidisciplinary panel of speakers and will feature panel discussions, audience participation, and sharing of best practice.

The first conversation of the day will look to discuss the effect of Covid-19 on cardiovascular disease - what went well, what could we do better and how do we plan for the future?

Next, we will be discussing Heart Failure, with the panel focusing on what is considered evidence-based treatment, what is the link with Type 2 diabetes and who is the expert in managing these patients?

The third conversation of the day looks at the ABC of Cardiovascular Disease and will include detection, protection and perfection across the ABC agenda, including the importance of the forthcoming Primary Care Network CVD DES .

Finally, we will close the afternoon with a conversation around blood clots, Covid-19 and the vaccine. 

View the full agenda and line up of speakers by clicking on the Agenda tab below.

Please note, this meeting is for PCCS members only as it forms part of the new PCCS CVD Academy.

If you are not a member but would like to attend this meeting, please read more about becoming a member here .

This meeting is supported by unrestricted grants from Bayer, Daiichi-Sankyo and Novartis who have had no input into the faculty or content. 
Sponsored by Boehringer-Ingelheim & Lilly Diabetes Alliance (The Alliance). BI-Lilly Alliance did not have any involvement or influence in selection of faculty, development of agenda or contents for these educational resources.